Johnson & Johnson to Participate in the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 12/12/24
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost OverThe Motley Fool • 12/12/24
CARVYKTI® (ciltacabtagene autoleucel) demonstrated significantly higher rates of minimal residual disease (MRD) negativity compared to standard therapies in the CARTITUDE-4 studyPRNewsWire • 12/10/24
Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment optionsPRNewsWire • 12/09/24
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimens demonstrate improved rates of minimal residual disease (MRD) negativity and progression-free survival in patients with newly diagnosed multiple myelomaPRNewsWire • 12/09/24
TECVAYLI® (teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myelomaPRNewsWire • 12/08/24
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myelomaPRNewsWire • 12/08/24
5 Relatively Secure And Cheap Dividend Stocks For December 2024: Yields Up To 9%Seeking Alpha • 12/07/24
Johnson & Johnson seeks U.S. FDA approval for first pediatric indications for TREMFYA® (guselkumab)PRNewsWire • 12/02/24
U.S. FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 Biosimilar to J&J's Stelara® (Ustekinumab)PRNewsWire • 12/02/24
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core HoldingSeeking Alpha • 11/28/24
Strategic ETF Allocations: Enhancing Income, Diversification, And Reducing Risks In Your Dividend PortfolioSeeking Alpha • 11/26/24